Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come.

Scarlett UK, Chang DC, Murtagh TJ, Flaherty KT.

Cancer Discov. 2016 Sep;6(9):956-62. doi: 10.1158/2159-8290.CD-16-0440.

2.

Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy.

Scarlett UK, Conejo-Garcia JR.

Expert Rev Obstet Gynecol. 2012 Sep 1;7(5):413-419.

3.

Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ.

Cancer Res. 2013 Jul 1;73(13):3842-51. doi: 10.1158/0008-5472.CAN-12-1974. Epub 2013 May 23.

4.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

5.

Double agents in the war on cancer: leukocytes govern ovarian cancer progression.

Scarlett UK, Conejo-Garcia JR.

Oncotarget. 2012 Mar;3(3):226-7.

6.

Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, Cubillos-Ruiz JR, Jacobs AC, Gonzalez JL, Weaver J, Fiering S, Conejo-Garcia JR.

J Exp Med. 2012 Mar 12;209(3):495-506. doi: 10.1084/jem.20111413. Epub 2012 Feb 20.

7.

Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Cubillos-Ruiz JR, Baird JR, Tesone AJ, Rutkowski MR, Scarlett UK, Camposeco-Jacobs AL, Anadon-Arnillas J, Harwood NM, Korc M, Fiering SN, Sempere LF, Conejo-Garcia JR.

Cancer Res. 2012 Apr 1;72(7):1683-93. doi: 10.1158/0008-5472.CAN-11-3160. Epub 2012 Feb 3.

8.

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.

Cubillos-Ruiz JR, Martinez D, Scarlett UK, Rutkowski MR, Nesbeth YC, Camposeco-Jacobs AL, Conejo-Garcia JR.

Oncotarget. 2010 Sep;1(5):329-38.

9.

CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Nesbeth YC, Martinez DG, Toraya S, Scarlett UK, Cubillos-Ruiz JR, Rutkowski MR, Conejo-Garcia JR.

J Immunol. 2010 May 15;184(10):5654-62. doi: 10.4049/jimmunol.0903247. Epub 2010 Apr 16.

10.

In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.

Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, Ahonen CL, Conejo-Garcia JR.

Cancer Res. 2009 Sep 15;69(18):7329-37. doi: 10.1158/0008-5472.CAN-09-0835. Epub 2009 Sep 8.

11.

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.

Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR.

J Clin Invest. 2009 Aug;119(8):2231-44. doi: 10.1172/JCI37716. Epub 2009 Jul 13.

12.

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.

Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR.

Cancer Res. 2009 Aug 1;69(15):6331-8. doi: 10.1158/0008-5472.CAN-08-4329. Epub 2009 Jul 14.

13.

Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR.

Cancer Res. 2008 Sep 15;68(18):7684-91. doi: 10.1158/0008-5472.CAN-08-1167. Epub 2008 Sep 3.

14.

PILAR is a novel modulator of human T-cell expansion.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR.

Blood. 2008 Aug 15;112(4):1259-68. doi: 10.1182/blood-2007-12-130773. Epub 2008 Jun 12.

Supplemental Content

Loading ...
Support Center